The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study
Abstract
Purpose To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer.Experimental design Patients with advanced breast cancer refractory to at least one chemotherapy regimen (ER negative tumors) or two hormonal regimens (ER positive tumors) were treated with troglitazone at 800 mg p.o. QD until disease progression, to determine the percentage of patients free of progression at 6 months. Tumor response, toxicity, and changes in serum tumor markers (CEA, CA27.29) that might reflect alteration in tumor differentiation, were also examined.Results Twenty-two patients were enrolled before suspension of protocol accrual and treatment when troglitazone was withdrawn from commercial availability following FDA warnings on hepatic toxicity. No objective responses (CR or PR) were observed; only three patients had SD at 8 weeks. Patients came off study for PD (16), DLT (1), FDA withdrawal (2), or other (3) reasons. No patients took troglitazone for more than 20 weeks; all had experienced disease progression or began other systemic therapy within 6 months. All patients with elevated serum tumor markers (CEA and CA27.29) at baseline had rising tumor markers within 8 weeks.Conclusions While clinical trials among different patient populations might uncover subtle effects on tumor differentiation, PPARgamma activation by troglitazone has little apparent clinical value among patients with treatment-refractory metastatic breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only a few clinical trials of TZDs for cancer treatment have been conducted, and results have largely been negative (108).”
From Diabetes and Cancer (2010) · cites this paper as [108]
Citations
Cites
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Self-citationAdipogenesis and Obesity: Rounding Out the Big Picture
Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,262
Self-citationTerminal Differentiation of Human Breast Cancer through PPARγ
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 850
Self-citationElstner, E., Müller‐Tidow, C., Koshizuka, K., Williamson, E. A., Park, D. J., Asou, H., Shintaku, P. I., SAID, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 804
Willson, T. M., Cobb, J. E., Cowan, D. J., Wiethe, R. W., Correa, I. D., Prakash, S. R., Beck, K. D., Moore, L. B., Kliewer, S. A., & Lehmann, J. M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950395a · Cited by 637
Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589
Demetri, G. D., Fletcher, C. D. �., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., & Singer, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3951 · Cited by 495
Self-citationMueller, E., Smith, M. R., Sarraf, P., Kroll, T. G., Aiyer, A., Kaufman, D. S., Oh, W. K., Demetri, G. D., Figg, W. D., Zhou, X.-P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180329197 · Cited by 427
Self-citationNonhypoglycemic Effects of Thiazolidinediones
Parulkar, A., Pendergrass, M., Granda-Ayala, R., Lee, T. R., & Fonseca, V. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00014 · Cited by 412
Lessons from the glitazones: a story of drug development
Gale, E. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04960-6 · Cited by 289
APC-dependent suppression of colon carcinogenesis by PPARγ
Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P. R., Rosenberg, D. W., Bronson, R. T., Edelmann, W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162480299 · Cited by 275
Self-citationSuh, N., Wang, Y., Williams, C. R., Risingsong, R., Gilmer, T. M., Willson, T. M., & Sporn, M. B. (1999) · PubMed · Cited by 230
Rubin, G., Zhao, Y., Kalus, A. M., & Simpson, E. R. (2000) · PubMed · Cited by 188
Troglitazone Inhibits Growth of MCF-7 Breast Carcinoma Cells by Targeting G1 Cell Cycle Regulators
Yin, F., Wakino, S., Liu, Z., Kim, S., Hsueh, W. A., Collins, A. R., Herle, A. J. V., & Law, R. E. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5491 · Cited by 143
Mehta, R. G. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.418 · Cited by 142
Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer
Esteva, F. J., Glaspy, J. A., Baidas, S. M., Laufman, L. R., Hutchins, L. F., Dickler, M. N., Tripathy, D., Cohen, R., DeMichele, A. M., Yocum, R. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.068 · Cited by 115
Self-citationSpencer, C. M., & Markham, A. (1997) · Drugs · doi:10.2165/00003495-199754010-00010 · Cited by 93
Pignatelli, M., Cortés‐Canteli, M., Lai, C., Santos, Á., & Pérez‐Castillo, A. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.22.4117 · Cited by 58
PPARγ and colorectal carcinoma: Conflicts in a nuclear family
Seed, B. (1998) · Nature Medicine · doi:10.1038/1990 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 1
- Demetri GD, Spiegelman B, Fletcher CD et al.: Differentiation of liposarcomas in patients treated with PPAR γ ligand troglitazone: documentation of biological activity in myxoid/ round cell and pleomorphic subtypes. Proc AmSoc Clin Oncol 18: 535a, 1999 (abstract 2064)
Cited by
Sorted by citations
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Self-citationDiabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,082
Obesity and diabetes: the increased risk of cancer and cancer-related mortality
Gallagher, E. J., & LeRoith, D. (2015) · Physiological Reviews · doi:10.1152/physrev.00030.2014 · Cited by 806
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3214 · Cited by 506
Metadata
- Authors
- Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Venue
- Breast Cancer Research and Treatment
- Published
- 2003-06
- Volume
- 79
- Issue
- 3
- Pages
- 391-397
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W1968980738
- Cited by
- 228
- References
- 21
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 14 · 2020: 5 · 2019: 7 · 2018: 13 · 2017: 11 · 2016: 5 · 2015: 3 · 2014: 4 · 2013: 10 · 2012: 18
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- troglitazone, PPARγ agonists, metastatic breast cancer, estrogen receptor-negative breast cancer, estrogen receptor-positive breast cancer, tumor markers, CEA, CA 27.29, tumor differentiation, drug toxicity, disease progression
- MeSH terms
- Troglitazone, Administration, Oral, Adult, Aged, Antineoplastic Agents, Breast Neoplasms, Chromans, Female, Humans, Liver, Middle Aged, Neoplasm Invasiveness, Thiazoles, Treatment Outcome, Disease Progression, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
